Dow Chemical Company’s Amicus Therapeutics FOLD Stock Holding History

Dow Chemical Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-14,674	Closed	-$221K	–	20
2017 Q3	$221K	Hold	14,674	–	–	0.05%	20
2017 Q2	$148K	Hold	14,674	–	–	0.02%	27
2017 Q1	$105K	Hold	14,674	–	–	0.01%	24
2016 Q4	$73K	Hold	14,674	–	–	0.01%	29
2016 Q3	$109K	Buy	+14,674	New	+$99.1K	0.01%	29
2016 Q2	–	Sell	-14,674	Closed	-$124K	–	26
2016 Q1	$124K	Hold	14,674	–	–	0.01%	26
2015 Q4	$142K	Buy	+14,674	New	+$132K	0.01%	24
2014 Q4	–	Sell	-22,162	Closed	-$132K	–	89
2014 Q3	$132K	Hold	22,162	–	–	0.01%	93
2014 Q2	$74K	Hold	22,162	–	–	0.01%	91
2014 Q1	$46K	Hold	22,162	–	–	﹤0.01%	86
2013 Q4	$52K	Hold	22,162	–	–	﹤0.01%	76
2013 Q3	$51K	Hold	22,162	–	–	﹤0.01%	72
2013 Q2	$52K	Buy	+22,162	New	+$68.1K	﹤0.01%	66

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Dow Chemical Company's FOLD Position: Q4 2017 in Review

Dow Chemical Company sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 14,674 shares — an estimated $221K sold.

Dow Chemical Company first reported a position in FOLD in Q2 2013 and held it in 13 quarters. The position peaked at $221K in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

Dow Chemical Company reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
Dow Chemical Company sold 14,674 Amicus Therapeutics shares in Q4 2017, an estimated $221K.
Dow Chemical Company first reported a position in Amicus Therapeutics in Q2 2013 and held it in 13 quarters.
Dow Chemical Company's Amicus Therapeutics position peaked at $221K in Q3 2017.
185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Dow Chemical Company's 13F filing for Q4 2017, filed 7 Feb 2018.